

Edgar Filing: CARESIDE INC - Form SC 13G/A

CARESIDE INC  
Form SC 13G/A  
February 11, 2003

February 11, 2003

Securities and Exchange Commission  
450 Fifth Street, N.W.  
Washington, DC 20549

Re: Schedule 13G - Careside, Inc.

Gentlemen:

Pursuant to Rule 13d-1 under the Securities and Exchange Act of 1934, as amended (the "Exchange Act") and Rule 13d-2 of the General Rules and Regulations promulgated pursuant to the Exchange Act, enclosed for filing electronically is Schedule 13G Amendment No. 2 filed by GlaxoSmithKline plc with respect to ownership of securities of Careside, Inc.

The Initial Statement and Amendment No. 1 were filed on February 14, 2000 and October 13, 2000 respectively and identify SmithKline Beecham Corporation ("SBCorp") as the Reporting Person. SBCorp and its affiliate, S.R.One, Limited, are current owners of record of the Careside shares.

GlaxoSmithKline plc, through a scheme of arrangement effective December 27, 2000, became the ultimate parent of SBCorp, and is identified as the Reporting Person in this filing.

Any questions concerning this filing may be directed to the undersigned at 215-751-7633.

Very truly yours,

/s/  
S.M. Bicknell  
Company Secretary

cc w/encs: Careside, Inc.

SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

SCHEDULE 13G

Under the Securities Exchange Act of 1934

(Amendment No. 2)\*

CARESIDE, INC.

-----  
(Name of Issuer)

Common Stock, \$.01 Par Value

-----  
(Title of Class of Securities)

141728 10 5  
-----



Edgar Filing: CARESIDE INC - Form SC 13G/A

9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
1,256,421

10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES  
[x]\*

11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9  
6.3%

12 TYPE OF REPORTING PERSON\*  
CO

\*Aggregate amount does not include securities held by Ms. Diana Mackie, an employee of the Reporting Person and a Director of Careside, Inc., beneficial ownership of which is disclaimed.

\*SEE INSTRUCTION BEFORE FILLING OUT!

CUSIP NO. 141728 10 5 13G PAGE 3 OF 4 PAGES

Item 1. (a) Name of Issuer:  
(b) Address of Issuer's Principal Executive Offices:

Item 2. (a) Name of Person Filing:  
GlaxoSmithKline plc  
(b) Address of Principal Business office:  
980 Great West Road  
Brentford  
Middlesex  
TW8 9GS  
ENGLAND

(c) Citizenship:  
England and Wales

(d) Title of Class of Securities:

(e) CUSIP Number:

Item 3. Not Applicable.

Item 4. Ownership.

The information in items 1 and 5 through 11 on the cover pages (page 2) on Schedule 13G is hereby incorporated by reference.

CUSIP NO. 141728 10 5 13G PAGE 4 OF 4 PAGES

Item 5. Ownership of Five Percent or Less of a Class:

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [ ].

## Edgar Filing: CARESIDE INC - Form SC 13G/A

SROne has the option to convert the remaining principal and accrued interest on the \$2 million bridge loan (the "Remaining Loan") into shares of Preferred Stock at \$6.375 per share. As of December 31, 2002, SROne was entitled to 431,927 shares. That total represents an increase of 70,567 shares over the number of shares reported in Amendment No. 1. Interest continues to accrue on the Remaining Loan at a rate of 10% (\$547.95/day). Payment of principal and interest and the continuing right to convert principal and interest are subject to the outcome of the Issuer's bankruptcy proceedings.

Item 6. Ownership of More Than Five Percent on Behalf of Another Person:

Item 7. Identification and Classification of Subsidiaries Which Acquired the Security Being Reported on by the Parent Holding Company:

Item 8. Identification and Classification of Members of the Group:

Item 9. Notice of Dissolution of Group:

Item 10. Certification:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of such securities and were not acquired in connection with or as a participant in any transaction having such purpose or effect.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

GLAXOSMITHKLINE PLC

By: /s/  
S.M. Bicknell  
Company Secretary

Dated: February 11, 2003